Vical has been hit with trial flop after trial flop, from cancer vaccines and herpes vaccines to just last week a cytomegalovirus (CMV) vaccine licensed from Astellas.
Now, with more than a touch of inevitability, the micro-cap biotech is letting go of around half of its workforce, trimming the number down from 74 staffers to a mere 34, in an attempt to save cash in the longer term.
This will also allow it to “focus its efforts on VL-2397, its antifungal drug product candidate which is entering a pivotal phase 2 clinical trial in the first quarter of 2018, and on completing its phase 2 HSV-2 clinical trial,” according to a statement.
Not included is this focus is the Astellas CMV program; earlier this month, Vical announced this vaccine, dubbed ASP0113, didn’t show a significant improvement in overall survival or reduction in CMV end-organ disease, missing the phase 3 trial’s primary composite endpoint, while also missing its secondary endpoints.
This is the second failure for the med after it also flopped in a midstage kidney transplant test. And it’s curtains for Vical’s work here: “The company is terminating all activities related to the ASP0113 program licensed to Astellas Pharma,” it said.
“We have carefully evaluated our organization and priorities and are restructuring to extend our cash runway to ensure that our promising HSV-2 vaccine candidate and VL-2397 antifungal drug product candidate is adequately resourced to maximize shareholder value,” said Vijay Samant, Vical’s president and CEO.
“This has been a very difficult process and we regret the impact this business decision has on our departing employees. We greatly appreciate the hard work and commitment they have shown Vical over the years and wish them the very best in their future endeavors.”
Last night, Vical’s shares were marginally up after hours, although its market cap is just $18 million. It ended 2017 with cash and investments of around $60 to $65 million, it says, and expects this to get it to the end of next year.
By Ben Adams
Source: Fierce Biotech
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.
Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.